Deauville criteria predicts outcome in Hodgkin lymphoma, particularly considering the high specificity of this imaging modality.

However, we strongly disagree with this conclusion. First, the fact that posttreatment ^{18}F-FDG PET had a sensitivity of only 25% indicates that most patients who are not cured actually have negative posttreatment ^{18}F-FDG PET findings. This is due to the limited spatial resolution of PET, as a result of which residual disease can never be excluded (*4*), as has been shown by several studies (*5*). The diagnostic performance of a test comprises both sensitivity and specificity. Any test with such a low sensitivity can generate a high specificity if the threshold to define positivity is simply raised. The combination of the very low sensitivity and the generally good prognosis of patients with Hodgkin lymphoma underlines that the number of patients needed to be scanned in order to detect one case of residual disease is actually quite high. ^{18}F-FDG PET scans are expensive, are not available in all institutions, provide ionizing radiation, and cause discomfort to the patient. Furthermore, according to the study of Bakhshi et al. and several other studies (*6*), the false-positive rate of posttreatment ^{18}F-FDG PET is actually very high. This applies to both the Revised International Workgroup criteria and the Deauville criteria, with false-positive rates of 85.7% and 66.7%, respectively, in the study by Bakhshi et al. (*1*). Awareness of this high false-positive rate is of the utmost importance, because it may result in unjustified initiation of second-line therapies and erroneous prognostication (if biopsy confirmation of ^{18}F-FDG–avid lesions is not possible), lead to a high number of unnecessary conformational biopsies, and cause unnecessary patient anxiety. The fact that an early ^{18}F-FDG PET–based detection of residual disease has not been proven to improve patient outcome further nullifies the need to acquire posttreatment ^{18}F-FDG PET scans (*7*).

In conclusion, interim ^{18}F-FDG PET fails to predict outcome in Hodgkin lymphoma, and posttreatment ^{18}F-FDG PET scans have a strikingly low sensitivity for the detection of residual disease. Furthermore, most ^{18}F-FDG–avid lesions seen on posttreatment ^{18}F-FDG PET scans appear to be false-positive findings. Therefore, neither interim nor posttreatment ^{18}F-FDG PET predicts outcome in Hodgkin lymphoma.

REFERENCES

1. Bakhshi S, Bhethanabhotla S, Kumar R, et al. Post-treatment PET-CT rather than interim PET-CT using Deauville criteria predicts outcome in pediatric Hodgkin lymphoma: a prospective study comparing PET-CT versus conventional imaging. *J Nucl Med.* October 6, 2016 [Epub ahead of print].
2. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. *J Clin Oncol.* 2007;25:579–586.
3. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. *J Clin Oncol.* 2014;32:3048–3058.
4. Adams HJ, Kwee TC. A negative ^{18}F-FDG-PET scan can never exclude residual disease. *Nucl Med Commun.* 2016;37:102–103.
5. Adams HJ, Nievelstein RA, Kwee TC. Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy. *Ann Hematol.* 2016;95:1–9.
6. Adams HJ, Kwee TC. Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: systematic review and meta-analysis. *Eur J Radiol.* 2016;85:1963–1970.
7. Jakobsen LH, Hutchings M, de Nully Brown P, et al. No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study. *Br J Haematol*. 2016;173:236–244.

Hugo J.A. Adams*
Thomas C. Kwee
**University Medical Center Utrecht*
Heidelberglaan 100, 3584 CX
Utrecht, The Netherlands
E-mail: h.j.a.adams@gmail.com

Published online Nov. 10, 2016.
DOI: 10.2967/jnumed.116.186023

REPLY: In reply to Adams et al., we would like to state that our study assessed the prognostic significance of interim and posttreatment PET with low-dose CT (PET/CT) in pediatric Hodgkin lymphoma in comparison to conventional imaging (*1*). In a disease with high cure rates, the purpose of evaluation with PET/CT is to identify high-risk patients and potentially prevent overtreatment of low-risk patients.

In our study, we found the sensitivity of posttreatment PET/CT and contrast-enhanced CT (CECT) to be equally low; however, the specificity of PET/CT was significantly high as compared with CECT (76.4% vs. 95.7%). This finding was also observed in a previously reported study by Furth et al. on pediatric Hodgkin lymphoma (*2*), establishing the fact that although PET/CT may not detect minimal residual disease, PET/CT can reasonably rule out active disease as compared with CECT. In our study, false-positive posttreatment findings were present in 21.8% of patients on CECT, as compared with 3.9% of patients on PET/CT; hence, PET/CT in effect may alleviate unnecessary patient anxiety about the presence of residual disease in an otherwise curable disease.

In the study cited by Adams et al. (*3*), the metaanalysis of the proportion of false-positive posttreatment PET/CT findings in adults with lymphoma also showed a high false-positive rate, 23.1%; however, unlike our study, comparison with conventional imaging was not done. In our study, if only posttreatment CECT had been used for response assessment, 23.6% of the patients would have required additional further evaluation with biopsy or (if biopsy was not possible) follow-up imaging to rule out disease. This percentage is higher than that for PET/CT; by use of the Deauville criteria, 5.8% of patients were PET/CT-positive after treatment. In contrast to the conclusion of Adams et al., posttreatment PET/CT can decrease unnecessary invasive procedures and patient anxiety when compared with CECT because of the better specificity of PET/CT. This observation was also reported in a cost-effectiveness analysis of posttreatment PET/CT in a study by Cerci et al. (*4*).

On the basis of two large studies that evaluated the role of PET/CT in Hodgkin lymphoma using the Deauville criteria, posttreatment PET/CT is more valuable in detecting primary refractory disease than in predicting relapse (*5,6*). In those studies, 60% of patients with positive interim PET/CT findings had primary refractory disease at the end of treatment, suggesting that PET/CT identified primary refractory disease (disease unresponsive to first-line chemotherapy) better than it identified patients with minimal residual disease who would relapse. Response to salvage chemotherapy and long-term outcome differ between these two scenarios (*7*). This also explains the inferior survival observed in our patients with positive PET/CT findings after treatment and underscores the utility of PET/CT in identifying primary refractory disease rather than predicting relapse.

We agree that routine use of PET/CT for response evaluation is not mandatory. However, in patients with risk factors for poor

outcome and patients with a residual mass at the end of treatment, PET/CT may obviate further imaging or invasive tests if the results turn out to be negative, and if positive it may identify patients with primary refractory disease who require further evaluation.

REFERENCES

1. Bakhshi S, Bhethanabhotla S, Kumar R, et al. Post-treatment PET-CT rather than interim PET-CT using Deauville criteria predicts outcome in pediatric Hodgkin lymphoma: a prospective study comparing PET-CT versus conventional imaging. *J Nucl Med.* October 6, 2016 [Epub ahead of print].
2. Furth C, Steffen IG, Amthauer H, et al. Early and late therapy response assessment with [^{18}F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial. *J Clin Oncol.* 2009;27:4385–4391.
3. Adams HJ, Kwee TC. Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: systematic review and meta-analysis. *Eur J Radiol.* 2016;85:1963–1970.
4. Cerci JJ, Trindade E, Pracchia LF, et al. Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy. *J Clin Oncol.* 2010;28:1415–1421.
5. Gallamini A, Barrington SF, Biggi A, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. *Haematologica.* 2014;99:1107–1113.
6. Hutchings M, Kostakoglu L, Zaucha JM, et al. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. *J Clin Oncol.* 2014;32:2705–2711.
7. Puig N, Pintilie M, Seshadri T, et al. Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma. *Haematologica.* 2010;95:1496–1502.

Sainath Bhethanabhotla
Sameer Bakhshi*
**Dr. B. R.A. Institute Rotary Cancer Hospital*
All India Institute of Medical Sciences
New Delhi 110 029, India
E-mail: sambakh@hotmail.com

Published online Dec. 8, 2016.
DOI: 10.2967/jnumed.116.186114